FOSTER CITY, CA--(Marketwire - November 23, 2009) - SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that it will present at the upcoming Piper Jaffray Annual Healthcare Conference in New York City. Friedhelm Blobel, Ph.D., SciClone's President and Chief Executive Officer, will present a corporate overview and business update on Tuesday, December 1, 2009 at 11:00 am ET.
To access the live audio webcasts of the presentations, please log on through a link located in the Investor Relations section of SciClone's website at www.sciclone.com.
About SciClone
SciClone Pharmaceuticals (NASDAQ: SCLN) is a profit-driven, global
specialty pharmaceutical company with a substantial international business
and a product portfolio of novel therapies for cancer and infectious
diseases. SciClone is focused on continuing international sales growth, a
cost-containing clinical development strategy, and overall expense
management. ZADAXIN® (thymalfasin or thymosin alpha 1) is sold in over 30
countries for the treatment of hepatitis B (HBV) and hepatitis C (HCV),
certain cancers and as a vaccine adjuvant. SciClone's pipeline of drug
candidates includes thymalfasin, in preclinical studies as an enhancer of
H1N1 flu vaccines; thymalfasin for stage IV melanoma, for which SciClone
has reached agreement with the FDA on the design of a phase 3 trial; SCV-07
in a phase 2 trial for the delay of onset of severe oral mucositis in
patients receiving chemoradiation therapy for the treatment of cancers of
the head and neck; and SCV-07 in a phase 2 trial for the treatment of HCV.
SciClone has exclusive commercialization and distribution rights to DC
Bead™ in China, where the product is under regulatory review. The
Company also has exclusive commercialization and distribution rights to the
anti-nausea drug ondansetron RapidFilm™ in China and Vietnam, for which
it will seek regulatory approval. For additional information, please visit
www.sciclone.com.
